Zobrazeno 1 - 10
of 493
pro vyhledávání: ''
Publikováno v:
Journal of Gastroenterology and Hepatology. 36:3308-3313
BACKGROUND AND AIM Vonoprazan has more potent and sustained acid inhibitory effects than proton pump inhibitors; therefore, Helicobacter pylori eradication rates are expected to improve with the use of vonoprazan-based regimens. To date, no randomize
Autor:
Ming-Wun Wong, Lin Lin, Tso-Tsai Liu, Jui-Sheng Hung, William C. Orr, Wei-Yi Lei, Shu-Wei Liang, Chih-Hsun Yi, Chien-Lin Chen
Publikováno v:
Journal of Gastroenterology and Hepatology. 36:3381-3386
Background and aim Opioid receptors agonists have been demonstrated to impair lower esophageal sphincter (LES) relaxation and induce spastic esophageal dysmotility, but little was known for their impact on distension-induced secondary peristalsis. Th
Autor:
Valentine Bordier, Fritz Murray, Joelle Buehler, Stéphanie Giezendanner, Daniel Pohl, Lukas Van Oudenhove, Valeria Schindler, Juliane Marie Hente
Publikováno v:
Journal of Gastroenterology and Hepatology. 36:3322-3328
BACKGROUND AND AIM Previous studies have shown a reduction of gastrointestinal symptoms in irritable bowel syndrome (IBS) patients following a low FODMAP diet (LFD). It remains unknown which disorders of gut-brain interaction (DGBI) patients would be
Publikováno v:
Journal of Gastroenterology and Hepatology. 36:2640-2648
Background and aim Vedolizumab is a novel monoclonal antibody used in patients with inflammatory bowel disease, often affecting women of child-bearing age. We aimed to compare maternal and fetal adverse outcomes in pregnancies of women with inflammat
Autor:
Carlos Castaño Milla, Lorena Sancho Del Val, José Antonio Olmos Jerez, Sandra Agudo-Fernández, Isabel Calvo Morillas, Ana González Blanco
Publikováno v:
Journal of Gastroenterology and Hepatology. 36:2794-2802
BACKGROUND AND AIM Atrial fibrillation is a major cause of death and disability due to stroke. Vitamin K antagonist drugs are effective for prevention, but they have a narrow therapeutic range and multiple pharmacological interactions. In recent year
Autor:
Cher Shiong Chuah, Ian D. Arnott, Nikolas Plevris, Gareth R. Jones, Wai Liam Lam, Rebecca Hall, Amy Tyler, S Siakavellas, Jayne Saunders, Philip Jenkinson, Claire Kane, Jennifer Veryan, Andrew Robertson, Graham Naismith, Gillian H Bain, Iona Campbell, L Potts, Christopher Kelly, Daniel R. Gaya, Craig Mowat, H. Jafferbhoy, James Fulforth, John Paul Seenan, Diarmid Ian Sutherland, Charlie W. Lees, David Watts, Jonathan Macdonald
Publikováno v:
Journal of Gastroenterology and Hepatology. 36:2067-2075
BACKGROUND AND AIM Ustekinumab is a monoclonal antibody that targets interleukin-12/23. In Scotland, it was approved for the treatment of moderate to severe Crohn's disease in 2017. The objective of this study was to establish the real-world effectiv
Autor:
Sang Hoon Ahn, Soo Jin Kim, Do Young Kim, Beom Kyung Kim, Seung Up Kim, Jun Yong Park, Kyung Hyun Kim
Publikováno v:
Journal of Gastroenterology and Hepatology. 36:1317-1325
BACKGROUND AND AIMS Recently, lenvatinib demonstrated non-inferiority to sorafenib in terms of overall survival (OS) in a randomized phase III study that was conducted at 154 sites in 20 countries. Here, we investigated treatment outcomes and safety
Autor:
Wei-Chen Tai, Keng-Liang Wu, Chih-Chien Yao, Seng-Kee Chuah, Chien-Ning Hsu, Chih-Ming Liang, Cheng-Kun Wu, Shih-Cheng Yang
Publikováno v:
Journal of Gastroenterology and Hepatology. 36:1828-1835
BACKGROUND AND AIM Clopidogrel is widely prescribed for patients with of aspirin-related upper gastrointestinal bleeding (UGIB) history. This study aimed to compare the risk of a major adverse cardiovascular event (MACE), UGIB, and mortality between
Autor:
Weiquan Li, Andrew Kwek, Prem Harichander Thurairajah, Tiing Leong Ang, Yu Bin Tan, Loshini Senthil Kumar, Ngai Moh Law, Zheng Cong Lee, Eng Kiong Teo, Kwong Ming Fock, Rajesh Kumar, Jingyun Koh, Jessica Tan, Yu Jun Wong
Publikováno v:
Journal of Gastroenterology and Hepatology. 36:1300-1308
BACKGROUND AND AIM Real-world data on sofosbuvir/velpatasvir with and without ribavirin (SOF/VEL ± RBV), particularly among patients with genotype 3 (GT3) decompensated cirrhosis, prior treatment, coinfection, and hepatocellular carcinoma (HCC), are
Publikováno v:
Journal of Gastroenterology and Hepatology. 36:1159-1163
Amoxicillin and proton pump inhibitor dual Helicobacter pylori therapy has proved not to be reliably highly effective primarily because of traditional proton pump inhibitors' inability to maintain a high intragastric pH. Clarithromycin and proton pum